U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07690410) titled 'TMP-SMX for Non-HIV PCP: A Prospective Multicenter Study' on July 01.
Brief Summary: Pneumocystis jirovecii pneumonia (PCP) is a life-threatening opportunistic infection in immunocompromised patients. Non-HIV-related PCP has a rising incidence, faster progression, and higher mortality than HIV-associated cases. Trimethoprim-sulfamethoxazole (TMP/SMX) is first-line, but standard dosing (TMP 15-20 mg/kg/day) is associated with adverse reaction rates of 56%-72%, and prospective evidence is scarce. This prospective, multicentre, observational study aims to compare the efficacy and safety of low-dose (TMP =18 years with confirmed non-HIV-...